NSCLC: Influence of Nivolumab plus Ipilimumab on Long-Term Overall survival

被引：0
|
作者：
Manych, Matthias
机构：
来源：
PNEUMOLOGIE | 2020年 / 74卷 / 03期
关键词：
D O I：
10.1055/a-1078-5162
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：130 / 130
页数：1
相关论文
共 50 条
  • [21] Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis
    Borghaei, H.
    Ciuleanu, T. -E.
    Lee, J. -S
    Pluzanski, A.
    Caro, R. Bernabe
    Gutierrez, M.
    Ohe, Y.
    Nishio, M.
    Goldman, J.
    Ready, N.
    Spigel, D. R.
    Ramalingam, S. S.
    Paz-Ares, L. G.
    Gainor, J. F.
    Ahmed, S.
    Reck, M.
    Maio, M.
    O'Byrne, K. J.
    Memaj, A.
    Nathan, F.
    Tran, P.
    Hellmann, M. D.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2023, 34 (02) : 173 - 185
  • [22] Malignant melanoma: overall survival after combined nivolumab ipilimumab therapy
    Krome, Susanne
    AKTUELLE DERMATOLOGIE, 2018, 44 (03) : 87 - 87
  • [23] Long Term Survival in Operable Stage Iiia Nsclc Patients Treated With Neoadjuvant Nivolumab Plus Chemotherapy - Nadim Study
    Provencio, M.
    Nadal, E.
    Insa, A.
    Garcia Campelo, M. R.
    Pereiro, D.
    Domine, M.
    Majem, M.
    Rodriguez Abreu, D.
    Martinez-Marti, A.
    De Castro, J.
    Cobo, M.
    Lopez Vivanco, G.
    Del Barco, E.
    Bernabe, R.
    Vinolas, N.
    Barneto, I.
    Viteri, S.
    Pereira, E.
    Royuela, A.
    Casarrubios, M.
    Salas, C.
    Parra, E. R.
    Wistuba, I.
    Calvo, V.
    -Briviesca, R. Laza
    Romero, A.
    Massuti, B.
    Cruz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S883 - S883
  • [24] First-Line Nivolumab plus Ipilimumab (NIVO plus IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227
    Borghaei, H.
    Brahmer, J. R.
    Lee, J. -S.
    Ciuleanu, T. -E.
    Caro, R. Bernabe
    Nishio, M.
    Urban, L.
    Audigier-Valette, C.
    Lupinacci, L.
    Sangha, R.
    Paz-Ares, L. G.
    Reck, M.
    O'Byrne, K. John
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Blum, S. I.
    Eccles, L.
    Ramalingam, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E8 - E9
  • [25] Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma
    Gibney, Geoffrey T.
    Atkins, Michael B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1873 - U27
  • [26] First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma
    Turajlic, S.
    Gore, M.
    Larkin, J.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 542 - 543
  • [27] Nivolumab Plus Ipilimumab Continues to Improve Survival in Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (06) : 336 - 336
  • [28] Chance of Long-term Survival through Checkpoint Blockade with Nivolumab
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (06) : 4 - 5
  • [29] Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
    Maloney, Anna K.
    Giobbie-Hurder, Anita
    Katukota, Nikita
    Fogarasi, Miklos C.
    Ott, Patrick A.
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan
    Buchbinder, Elizabeth, I
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (08)
  • [30] The overall safety and short-term efficacy of nivolumab plus ipilimumab for advanced esophageal squamous cell carcinoma.
    Shiraishi, Kazuhiro
    Yamamoto, Shun
    Yoshinami, Yuri
    Ohara, Akihiro
    Itoyama, Mai
    Yokoyama, Kazuki
    Honma, Yoshitaka
    Kashiraha, Tairo
    Kurita, Daisuke
    Ishiyama, Koshiro
    Oguma, Junya
    Igaki, Hiroshi
    Daiko, Hiroyuki
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 329 - 329
12345